YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
Status:
Recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind,
placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The
MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy
subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label,
multiple ascending dose study in patients with coronary atherosclerosis.